Category: MS Research Study and Reports

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial

 Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; et al Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6 Author Affiliations Article Information JAMA Neurol. Published online January 23, 2023. doi:10.1001/jamaneurol.2022.5007 Key Points Question  Does proposed biosimilar…

Stuart Schlossman

Almost No Cases Found of Celiac Disease and MS in New Analysis / Investigating links between celiac disease and MS

 Prevalence of gluten-caused disease in MS patients is close to zero by Patricia Inacio, PhD | January 18, 2023 This…

Stuart Schlossman

A discovery at the Oklahoma Medical Research Foundation is shedding new light on a particularly devastating form of multiple sclerosis: PPMS

  January 10, 2023 OMRF scientists say their finding could lead to a treatment breakthrough for primary-progressive MS, which may…

Stuart Schlossman

FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS

By Lindsey Shapiro, PhD on 01/03/2023 The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3…

Stuart Schlossman

Antidepressant Bupropion Found to Ease Sexual Dysfunction in MS

 Dec 2022 Daily treatment with an oral antidepressant called bupropion — marketed as Wellbutrin and Zyban, among others — significantly improved some…

Stuart Schlossman

Under the microscope: what is the potential of BTK inhibitors (BTKI) ?

information provided by: MS Society UK  Bruton’s tyrosine kinase (BTK) inhibitors are an emerging type of disease modifying therapy (DMT)…

Stuart Schlossman

The MS wealth death gap. Rich people with MS are 16.6% more likely to be alive after 30 years compared with poor people with MS [according to this observational study in France].

  Abstract Background: The effects of socio-economic status on mortality in patients with multiple sclerosis is not well known. The objective…

Stuart Schlossman

Can diabetes drugs like insulin, metformin affect MS risk?

 Medical New Today By Hannah Flynn on November 24, 2022 — Fact checked by Anna Guildford, Ph.D.      …

Stuart Schlossman

Time to reconsider the classification of multiple sclerosis

 author: Takashi Yamamura November 18, 2022 Multiple sclerosis is an inflammatory demyelinating disease of the CNS, showing various clinical manifestations…

Stuart Schlossman

Multiple sclerosis progression: time for a new mechanism-driven framework

Published: November 18, 2022 Prof Tanja Kuhlmann, MD  Marcello Moccia, MD Timothy Coetzee, PhD * Prof Jeffrey A Cohen, MD * Prof…

Stuart Schlossman

Categories

Latest Blog Posts